Short answer
Rezolute, Inc. (RZLT) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Rezolute announced financial results for Q1 ended September 30, 2026.
Rezolute, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Rezolute announced financial results for Q1 ended September 30, 2026
- Full financial figures and management commentary are in Exhibit 99.1, the attached earnings release
Item EX-99.1 · Exhibit EX-99.1
- Cash, equivalents and marketable investments $90.0M, down from $107.8M, highlighting continued financing needs
- Net loss $18.5M, or $0.18 per share, versus $18.2M and $0.18 in the prior-year quarter
- Tumor HI enrollment complete, with topline Phase 3 upLIFT results expected by mid-December 2026
- FDA recommended a BLA filing for congenital HI, despite sunRIZE missing its primary endpoint
- Rezolute plans potential BLA submissions for one or both indications in 2027, targeting a stated $5B combined market opportunity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Rezolute, Inc. 8-K filings
Get the next RZLT 8-K as it lands
Follow RZLT for push alerts, or ask the research agent what this filing means.